Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal

Drew Armstrong

Executive Editor

Amber Tong

French drugmaker Sanofi showcased its vaccine franchise, part of a promise made two years ago to overhaul what the company at the time acknowledged was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal

Drew Armstrong

Executive Editor

Amber Tong

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

Exclusive: Florida cancer biotech raises $100M Series A

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Sanofi hints at 'class ef­fec­t' for mR­NA flu shot as it un­veils vac­cine R&D plans dri­ven by $3.2B deal

Executive Editor

Sign up to read this article for free.

more like this

Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal